Tech Company Financing Transactions
Enobia Pharma Funding Round
Private investors participated in a $40 million capital raise for Enobia Pharma. The round was announced on 8/9/2011.
Transaction Overview
Company Name
Announced On
8/9/2011
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds will be used to fund the ongoing development of ENB-0040, Enobia's enzyme replacement therapy (ERT) for hypophosphatasia, a rare and potentially life threatening genetic bone disorder for which there is no currently approved therapy.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Parkway 800
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Not Recorded
Overview
Enobia Pharma is a developer of enzyme replacement therapies for the treatment of serious bone diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Heft
Chief Financial Officer
Jeff Mack
Chief Medical Officer
Hal Landy
Chief Scientific Officer
Philippe Crine
VP - Finance
Luc Cournoyer
VP - General Counsel
Eric Trachtenberg
VP - Manufacturing
Bernhard Eggimann
VP - Regulatory Affairs
Deborah Ramsdell
Browse more venture capital transactions:
Prev: 8/9/2011: Hotlink venture capital transaction
Next: 8/9/2011: ZEFR venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs